COMP <GO>
COR vs UNH // EV/EBITDA & P/E VALUATION
Cencora Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: COR 4
— UNH 10
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $330.53 (+1.91%) • MKT CAP: $63.07B
valuation
21.6x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COR VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COR | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.60% | 88.57% | -84.97 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 26.80% | 11.47% | +15.33 | COR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.6x | 16.4x | +5.15 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 6.48% | -1.40 | UNH | /fcf-yield <GO> |
| Operating Margin | 0.80% | 4.82% | -4.02 | UNH | /operating-margins <GO> |
| Net Profit Margin | 0.50% | 3.14% | -2.64 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 9.30% | 6.46% | +2.84 | COR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.69% | 2.28% | -1.59 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.27 | 3.12 | +2.15 | COR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 59.2 | -5.40 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.33 | +0.55 | COR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 37.8x | 17.1x | +20.71 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $63.07B | $368.83B | -$305.76B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COR REV | UNH REV | COR GROSS % | UNH GROSS % | COR FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $321.33B | $447.57B | 3.6% | 88.7% | $3.21B | $16.07B |
| FY 2024 | $293.96B | $400.28B | 3.4% | 88.3% | $3.00B | $20.70B |
| FY 2023 | $262.17B | $371.62B | — | 89.6% | -$7.89B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COR // BETA 0.88
UNH // BETA 0.33